The FDA approves Valeant’s psoriasis drug; PhRMA to review its membership criteria; Lions Health announces pharma and health and wellness jury presidents
A Reformed FDA Under Trump Likely Means Uncertainty
The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their pricing houses in order?
Five things for pharma marketers to know: Tuesday, January 3, 2017
Sprout investors sue Valeant; FDA raises safety concerns for Cempra’s experimental pneumonia drug; NHS gets approval to prescribe eribulin to breast cancer patients
The FDA approves Amgen’s biosimilar version of Humira